(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), a clinical-stage
biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary
technological platform DOS47, today announces that it has closed a private placement financing for gross proceeds
of $1,001,000 from the issuance of 3,850,000 common share at a price of $0.26 per common share.
- 0 Comments
- FY2022